HUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded HUTCHMED to “buy” from “hold,” but the broader analyst consensus remains “Hold,” with an average price target of $14.87.
• HUTCHMED shares opened at $12.51, up 5.7%, while trading between a 52-week range of $9.77 to $18.30. The company’s latest quarterly results missed expectations, reporting $0.05 in EPS versus $0.14 expected and revenue of $139.14 million versus $304.16 million forecast.
• Institutional ownership stands at 8.82%, with several firms—including Jane Street and UBS—significantly increasing their stakes in the biopharmaceutical company.

HUTCHMED (NASDAQ:HCM - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

Other equities analysts also recently issued reports about the company. Bank of America lowered their price objective on HUTCHMED from $20.00 to $17.00 and set a "buy" rating for the company in a research report on Tuesday, July 7th. The Goldman Sachs Group cut their price objective on shares of HUTCHMED from $16.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday, July 23rd. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a research report on Thursday, May 28th. Finally, Weiss Ratings downgraded shares of HUTCHMED from a "hold (c-)" rating to a "sell (d)" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, HUTCHMED has an average rating of "Hold" and an average price target of $14.87.

HUTCHMED Stock Up 5.7%

Shares of HCM opened at $12.51 on Friday. HUTCHMED has a 52 week low of $9.77 and a 52 week high of $18.30. The stock has a fifty day moving average of $11.02 and a 200-day moving average of $13.09. The company has a current ratio of 5.64, a quick ratio of 5.50 and a debt-to-equity ratio of 0.06.

HUTCHMED (NASDAQ:HCM - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.09). The firm had revenue of $139.14 million during the quarter, compared to analysts' expectations of $304.16 million. As a group, research analysts forecast that HUTCHMED will post 0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp raised its stake in shares of HUTCHMED by 1.2% during the fourth quarter. State Street Corp now owns 321,305 shares of the company's stock worth $4,283,000 after acquiring an additional 3,801 shares in the last quarter. M&G PLC raised its position in shares of HUTCHMED by 26.7% in the 4th quarter. M&G PLC now owns 259,033 shares of the company's stock worth $3,367,000 after acquiring an additional 54,601 shares in the last quarter. Amundi lifted its position in HUTCHMED by 4.0% during the 1st quarter. Amundi now owns 232,246 shares of the company's stock valued at $3,474,000 after acquiring an additional 8,916 shares during the period. Jane Street Group LLC raised its stake in HUTCHMED by 128.0% during the first quarter. Jane Street Group LLC now owns 222,241 shares of the company's stock valued at $3,343,000 after buying an additional 124,771 shares during the last quarter. Finally, UBS Group AG lifted its stake in shares of HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company's stock worth $2,158,000 after buying an additional 72,614 shares in the last quarter. Institutional investors own 8.82% of the company's stock.

HUTCHMED Company Profile

HUTCHMED NASDAQ: HCM is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED's integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED's commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source